#IMID

Signal Transduction and Targeted Therapy

@sigtrans-sttt.bsky.social

3 weeks ago

Immune-Mediated Inflammatory Diseases are at the forefront of immunology and translational research. Explore cutting-edge discoveries shaping inflammation, tissue repair, and therapy in Signal Transduction and Targeted Therapy
www.nature.com/sigtrans/
#IMID #Immunology #Inflammation

@jyves94.bsky.social

8 months ago

FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma

La #FDA des #USA accorde une #FastTrack 🚀 au #Linvoseltamab 💊, un engageur #Bispécifique des lymphocytes T #CD3 dirigé vers #BCMA, pour le #MyélomeMultiple 🩸 R/R, qui ont reçu ≥4 LOT auparavant, y compris un IP, un #IMiD et un #AnticorpsMonoclonal anti- #CD38
www.fda.gov/drugs/resour...

Fraunhofer ITMP

@fraunhoferitmp.bsky.social

8 months ago

#HIPPOCRATES Annual Plenary Meeting& General Assembly 2025! Spannende Keynotes, Workshops & Updates rund um innovative IMID-Forschung. Gemeinsam mit europäischen Partnern gestalten wir die Zukunft der personalisierten Medizin.
#ITMP #IMID #Forschung @hippocrates-imi.bsky.social

CNAG

@cnag-eu.bsky.social

11 months ago

Relive the DocTIS webinar: "Discovery of combination therapies for Immune-Mediated Inflammatory Diseases" - Doctis In February 2025, the DocTIS project hosted an insightful webinar during one of its General Assemblies, marking a key milestone as the initiative enters its

🔎 Discover the latest advances in treatments for Immune-Mediated Inflammatory Diseases in the #DocTISProject #webinar

🗣️ Featuring @hoheyn.bsky.social, our Single Cell Genomics Group Leader, discussing molecular data generation from IMID Biobank patients

🔗 doctis.eu/relive-docti...
#IMID #CNAG